Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti- XXXX Agents for Wet Age-Related @entity1020 .

@entity1 @entity1020 @entity227 @entity7
PURPOSE: To report on long-term visual outcomes in @entity1 receiving continuous fixed-interval dosing of @entity7 ( @entity7 ) treatment in neovascular @entity1020 ( @entity1020 ). DESIGN: Single-practice retrospective chart review. @entity1 : One hundred nine eyes with exudative @entity1020 receiving continuous fixed-interval dosing (every 4-8 weeks) of anti- @entity7 therapy (ranibizumab, bevacizumab, or aflibercept) for at least 5 years. Eyes were excluded if they averaged fewer than 6.5 injections per year. METHODS: Snellen @entity227 was recorded at baseline and all subsequent injections. Changes from baseline were calculated at yearly intervals. MAIN OUTCOME MEASURES: The primary outcome measure was mean change in letter score at 5, 6, and 7 years; secondary outcomes included the percentage of @entity1 with 20/40 vision or better at 7 years and the mean change in letter score at each yearly time point based on baseline visual grouping (20/40 or better, 20/50-20/100, 20/200 or worse). RESULTS: Forty-four, 75, and 109 @entity1 with 7, 6, and 5 years, respectively, of continuous treatment were identified. Mean change in letter score at year 5 was  +14.0 letters (P  = 3.9  * 10(-9)),  +12.2 letters at 6 years (P  =  1.5  * 10(-7)), and  +12.1 letters at 7 years (P  = 3.8  * 10(-5)). Driving vision (20/40 or better) was achieved in 43.2% of treated eyes. Subanalysis revealed that the greatest visual gains at 5 and 7 years were seen in those @entity1 with baseline @entity227 worse than 20/200 (+24.5 and  +25.5 letters), followed by those with 20/50 to 20/100 vision (+6.7 and  +6.9 letters), and finally those with 20/20 to 20/40 (+3.7 and  +3.4 letters). @entity1 received an average of 10.5 injections per year. CONCLUSIONS: Continuous fixed-interval dosing of anti- @entity7 therapy in @entity1 with exudative @entity1020 results in favorable long-term preservation out to 7 years, with vision stabilizing or improving in 93.2% of eyes. Additionally, 43.2% of @entity1 maintained driving vision in the treatment eye at 7 years compared with 10.1% at baseline. Our data suggest better outcomes with continuous therapy over published results with sporadic, as-needed therapy.
